Wellgistics Health, Inc. has launched its diabetes drug Brenzavvy® to its pharmacy network, targeting the $16 billion SGLT-2 inhibitor market in the US. The company uses its EinsteinRx™ AI platform to assist pharmacists with patient education, aiming to reduce out-of-pocket costs and enhance patient access. This launch establishes a new model for reformulated drug introductions in the market.

WGRX

<p>Wellgistics Health, Inc. 已经向其药房网络推出了糖尿病药物 Brenzavvy®，瞄准美国 160 亿美元的 SGLT-2 抑制剂市场。该公司利用其 EinsteinRx™ AI 平台帮助药剂师进行患者教育，旨在降低患者自付费用并增强患者的可及性。这一推出为市场上重新配方药物的引入建立了新的模式</p>

Wellgistics Health 推出了糖尿病药物 Brenzavvy®